Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Other Sep 18 | 2020Diamyd to Move Forward with Ph3 Trial in HLA-Present T1DM Subpopulation; Additional Results from DIAGNODE-2Purchase Blast
$599
Posted in: CAR-T, CD123, CD22, CS1 Sep 18 | 2020Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Glucose Monitoring Sep 17 | 2020Abbott to Launch the First "Glucose Sport Biosensor"Purchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 17 | 2020Dexcom Announces New CGM Registry and Global Business Service Site in Lithuania; Dario Appoints Former LifeScan Exec to Scientific Advisory BoardPurchase Blast
$599
Posted in: Other Sep 16 | 2020Japanese NDA Submitted for Imeglimin; Poxel H1 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other, SGLT2i Sep 16 | 2020Apple Cites T1DM Omnipod Patient Story at Tuesday Event; Jardiance Post-MI Trial (EMPACT-MI) Receives FDA FTD; Adocia Topline Results from M1Pram Ph1b Trial Extension; Welldoc/UMD Employs AI to Identify Digital Health Habits; Oramed’s Positive Diabetes Market Survey Results; Diamyd Receives $13.9M Towards Companion Medical SharesPurchase Blast
$599
Posted in: Glucose Monitoring Sep 15 | 2020Senseonics Hosts Investor Event with Special Guest AscensiaPurchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 14 | 2020Diamyd's Ph2b DIAGNODE-2 Trial Topline Results; New MicroTech Medical BGM 510(k) Clearance; Voluntis Announces €2M in FundingPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, SGLT2i Sep 14 | 2020High-dose Trulicity, DAPA-HF and Gvoke up for Opinions; CHMP Agenda September 14-17Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Sep 11 | 2020Thoughts on Newly Permanent Lilly Insulin+Baqsimi Copay Cards; New Novo+ACC ASCVD Registry; ProSciento Receives VC InvestmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Sep 10 | 2020New Tirzepatide + Glargine U100 vs. Basal-Bolus Trial (SURPASS-6)Purchase Blast
$599
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Sep 08 | 2020Thoughts on Autolus's CAR-T Program; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Glucagon, Other Sep 04 | 2020Danilo Verge and David Kendall Join ZealandPurchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Sep 04 | 2020Gilead Highlights No Impact of COVID-19 on Yescarta Sales; Two New LCM Initiatives for Yescarta; Q2 2020 Earnings Call SummaryPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T Sep 03 | 2020bluebird bio Highlights Ide-cel Resubmission; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Other Sep 02 | 2020Former Head of BI Diabetes/CardioMetabolism Joins NovoPurchase Blast
$599
Posted in: Glucose Monitoring Sep 01 | 2020Libre 2 Available for Medicare Patients; Senseonics Receives Positive Medicare Local Coverage DeterminationsPurchase Blast
$599
Posted in: SGLT2i Sep 01 | 2020AZ Provides Additional DAPA-CKD Commentary During Post-Results Investor CallPurchase Blast